{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:10:52Z","timestamp":1789193452135,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005978","name":"Ministry of Health and Solidarity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jcf.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T01:06:57Z","timestamp":1622682417000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["HOMA indices as screening tests for cystic fibrosis-related diabetes"],"prefix":"10.1016","volume":"21","author":[{"given":"Tom","family":"Toin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-053X","authenticated-orcid":false,"given":"Quitterie","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mainguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-7920","authenticated-orcid":false,"given":"Sandrine","family":"Touzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Reix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2021.05.010_bib0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2021.05.010_bib0002","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2021.05.010_bib0003","unstructured":"Vaincre la Mucoviscidose. Registre fran\u00e7ais de la Mucoviscidose. Bilan des donn\u00e9es 2018. 2020. Available online: https:\/\/www.vaincrelamuco.org\/sites\/default\/files\/registre_francais_de_la_mucoviscidose_bilan_donnees_2018.pdf (accessed on 17 December 2020)."},{"issue":"5","key":"10.1016\/j.jcf.2021.05.010_bib0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"issue":"3 Pt 1","key":"10.1016\/j.jcf.2021.05.010_bib0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2021.05.010_bib0006","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2007.02.005","article-title":"Increased glucose excursion in cystic fibrosis and its association with a worse clinical status","volume":"6","author":"Costa","year":"2007","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"12","key":"10.1016\/j.jcf.2021.05.010_bib0007","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 27","key":"10.1016\/j.jcf.2021.05.010_bib0008","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents","volume":"19","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"10.1016\/j.jcf.2021.05.010_bib0009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2021.05.010_bib0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/pedi.12470","article-title":"Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females","volume":"18","author":"Haliloglu","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.jcf.2021.05.010_bib0011","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcjd.2016.08.221","article-title":"Screening for Cystic Fibrosis-Related Diabetes: Matching Pathophysiology and Addressing Current Challenges","volume":"40","author":"Boudreau","year":"2016","journal-title":"Can J Diabetes"},{"issue":"6","key":"10.1016\/j.jcf.2021.05.010_bib0012","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.diabet.2008.05.010","article-title":"No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes","volume":"34","author":"Godbout","year":"2008","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.jcf.2021.05.010_bib0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jcjd.2018.11.005","article-title":"Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis\u2013Related Diabetes in Adults","volume":"43","author":"Boudreau","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcf.2021.05.010_bib0014","doi-asserted-by":"crossref","unstructured":"Matthews DR, Hosker JR, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et\u00a0al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. 1985;28(7):412\u20139.","DOI":"10.1007\/BF00280883"},{"issue":"6","key":"10.1016\/j.jcf.2021.05.010_bib0015","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jcf.2021.05.010_bib0016","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2337\/dc06-0709","article-title":"Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study","volume":"29","author":"Lee","year":"2006","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jcf.2021.05.010_bib0017","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2337\/diabetes.53.7.1782","article-title":"Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Bruneck Study","volume":"53","author":"Bonora","year":"2004","journal-title":"Diabetes."},{"issue":"12","key":"10.1016\/j.jcf.2021.05.010_bib0018","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/dom.14149","article-title":"The effects of ertugliflozin on \u03b2-cell function: Pooled analysis from four phase 3 randomized controlled studies","volume":"22","author":"Gallo","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jcf.2021.05.010_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jpem-2016-0184","article-title":"Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?","volume":"30","author":"Mainguy","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jcf.2021.05.010_bib0020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1515\/jpem-2017-0122","article-title":"Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?","volume":"30","author":"Boudreau","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jcf.2021.05.010_bib0021","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcf.2017.09.010","article-title":"Glucose trajectories in cystic fibrosis and their association with pulmonary function","volume":"17","author":"Reynaud","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2021.05.010_bib0022","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5582\/ddt.2015.01207","article-title":"Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future","volume":"9","author":"Tang","year":"2015","journal-title":"Drug Discov Ther"},{"issue":"5","key":"10.1016\/j.jcf.2021.05.010_bib0023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.2040-1124.2011.00113.x","article-title":"Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population: HOMA-IR reference interval in Japanese","volume":"2","author":"Yamada","year":"2011","journal-title":"J Diabetes Investig"},{"issue":"4","key":"10.1016\/j.jcf.2021.05.010_bib0024","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.2004-1921","article-title":"Homeostasis model assessment is more reliable than the fasting glucose\/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents","volume":"115","author":"Keskin","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jcf.2021.05.010_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4274\/jcrpe.v2i3.100","article-title":"Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods","volume":"2","author":"Kurto\u011flu","year":"2010","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"10.1016\/j.jcf.2021.05.010_bib0026","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diabres.2013.10.021","article-title":"Prevalence of insulin resistance and cardiometabolic risk in Korean children and adolescents: A population-based study","volume":"103","author":"Yi","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10.1016\/j.jcf.2021.05.010_bib0027","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jcf.2021.05.010_bib0028","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/js.2017-00362","article-title":"Evolving mechanistic views and emerging therapeutic strategies for cystic fibrosis\u2013related diabetes","volume":"1","author":"Yoon","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jcf.2021.05.010_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179551419851770","article-title":"Cystic fibrosis-related diabetes: pathophysiology and therapeutic challenges","volume":"12","author":"Kelsey","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"6","key":"10.1016\/j.jcf.2021.05.010_bib0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jcf.2016.04.004","article-title":"Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity?","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:46:23Z","timestamp":1761601583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1569199321001612"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.05.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HOMA indices as screening tests for cystic fibrosis-related diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}